Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 3:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 390 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Breast Cancer, Estrogen Receptor-Positive Clear all
Active, not recruiting Phase 2 Interventional

CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer

NCT03285412
View directory record Official record
Conditions
Breast Cancer
Interventions
Ribociclib, Endocrine therapy
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts • Danvers, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Jun 25, 2026, 3:10 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

NCT05104866
View directory record Official record
Conditions
Breast Cancer
Interventions
Dato-DXd, Capecitabine, Gemcitabine, Eribulin, Vinorelbine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
14
States / cities
Duarte, California • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jun 25, 2026, 3:10 PM EDT
Completed Phase 1 Interventional

Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer

NCT02820961
View directory record Official record
Conditions
Breast Cancer, Estrogen Receptor Positive Breast Cancer
Interventions
entinostat, exemestane
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Denver, Colorado • Sarasota, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Jun 25, 2026, 3:10 PM EDT
Terminated Phase 2 Interventional Results available

Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score

NCT02236572
View directory record Official record
Conditions
Breast Cancer
Interventions
Everolimus
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Jun 25, 2026, 3:10 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

NCT02049957
View directory record Official record
Conditions
Breast Cancer
Interventions
Sapanisertib, Fulvestrant, Exemestane
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
30
States / cities
Los Angeles, California • San Francisco, California • Santa Barbara, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Jun 25, 2026, 3:10 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors

NCT01522820
View directory record Official record
Conditions
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Estrogen Receptor Negative, Estrogen Receptor Positive, Glioblastoma, Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Metastatic Renal Cell Cancer, Recurrent Adult Brain Neoplasm, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Hepatocellular Carcinoma, Recurrent Lung Carcinoma, Recurrent Melanoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Uterine Corpus Carcinoma, Resectable Hepatocellular Carcinoma, Sarcoma, Stage IA Breast Cancer, Stage IA Ovarian Cancer, Stage IA Uterine Corpus Cancer, Stage IB Breast Cancer, Stage IB Ovarian Cancer, Stage IB Uterine Corpus Cancer, Stage IC Ovarian Cancer, Stage II Uterine Corpus Cancer, Stage IIA Breast Cancer, Stage IIA Lung Carcinoma, Stage IIA Ovarian Cancer, Stage IIB Breast Cancer, Stage IIB Esophageal Cancer, Stage IIB Lung Carcinoma, Stage IIB Ovarian Cancer, Stage IIB Skin Melanoma, Stage IIC Ovarian Cancer, Stage IIC Skin Melanoma, Stage IIIA Breast Cancer, Stage IIIA Esophageal Cancer, Stage IIIA Lung Carcinoma, Stage IIIA Ovarian Cancer, Stage IIIA Skin Melanoma, Stage IIIA Uterine Corpus Cancer, Stage IIIB Breast Cancer, Stage IIIB Esophageal Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Skin Melanoma, Stage IIIB Uterine Corpus Cancer, Stage IIIC Breast Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Skin Melanoma, Stage IIIC Uterine Corpus Cancer, Stage IV Bladder Urothelial Carcinoma, Stage IV Esophageal Cancer, Stage IV Ovarian Cancer, Stage IV Prostate Cancer, Stage IV Skin Melanoma, Stage IVA Uterine Corpus Cancer, Stage IVB Uterine Corpus Cancer
Interventions
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study, Sirolimus
Biological · Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2016 · Synced Jun 25, 2026, 3:10 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Palbociclib With Everolimus + Exemestane In BC

NCT02871791
View directory record Official record
Conditions
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor (HR)-Positive Breast Cancer
Interventions
Palbociclib, Everolimus, Exemestane
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 28, 2022 · Synced Jun 25, 2026, 3:10 PM EDT
Not yet recruiting Phase 2 Interventional

Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial

NCT07191717
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Invasive Breast Carcinoma, Localized Estrogen Receptor-Positive Breast Carcinoma, Localized Human Epidermal Growth Factor Receptor (HER2)-Negative Breast Carcinoma
Interventions
Abemaciclib, Biospecimen Collection, Imlunestrant, Questionnaire Administration, Radiologic Imaging Procedure
Drug · Procedure · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Jun 25, 2026, 3:10 PM EDT
Active, not recruiting Phase 3 Interventional Results available

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

NCT01674140
View directory record Official record
Conditions
Breast Cancer
Interventions
anastrozole, everolimus, exemestane, goserelin acetate, letrozole, leuprolide acetate, tamoxifen citrate, placebo
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
1,939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
1455
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 887 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Jun 25, 2026, 3:10 PM EDT
Terminated Phase 2 Interventional Results available

Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery

NCT01754519
View directory record Official record
Conditions
Ductal Breast Carcinoma In Situ, Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Invasive Cribriform Breast Carcinoma, Invasive Ductal Carcinoma, Not Otherwise Specified, Lobular Breast Carcinoma In Situ, Mucinous Breast Carcinoma, Papillary Breast Carcinoma, Progesterone Receptor Positive, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Tubular Breast Carcinoma
Interventions
Therapeutic Conventional Surgery, Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Procedure · Radiation · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
50 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Jun 25, 2026, 3:10 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer

NCT01037790
View directory record Official record
Conditions
Adult Solid Tumor, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Adult Central Nervous System Germ Cell Tumor, Adult Teratoma, Benign Teratoma, Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Familial Testicular Germ Cell Tumor, HER2-negative Breast Cancer, HER2-positive Breast Cancer, Male Breast Cancer, Ovarian Immature Teratoma, Ovarian Mature Teratoma, Ovarian Monodermal and Highly Specialized Teratoma, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Extragonadal Germ Cell Tumor, Recurrent Extragonadal Non-seminomatous Germ Cell Tumor, Recurrent Extragonadal Seminoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Melanoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Rectal Cancer, Stage III Extragonadal Non-seminomatous Germ Cell Tumor, Stage III Extragonadal Seminoma, Stage III Malignant Testicular Germ Cell Tumor, Stage III Ovarian Germ Cell Tumor, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Extragonadal Non-seminomatous Germ Cell Tumor, Stage IV Extragonadal Seminoma, Stage IV Melanoma, Stage IV Ovarian Germ Cell Tumor, Stage IV Rectal Cancer, Testicular Immature Teratoma, Testicular Mature Teratoma
Interventions
PD-0332991
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Jun 25, 2026, 3:10 PM EDT
Completed Phase 2 Interventional

Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus

NCT02015559
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Oral Complications, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
mucoadhesive oral wound rinse, laboratory biomarker analysis
Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 20, 2020 · Synced Jun 25, 2026, 3:10 PM EDT
Completed Phase 3 Interventional Results available

A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

NCT01740427
View directory record Official record
Conditions
Breast Neoplasms
Interventions
PD-0332991, Letrozole, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
136
States / cities
Bellflower, California • Beverly Hills, California • Fullerton, California + 83 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Jun 25, 2026, 3:10 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

NCT02947685
View directory record Official record
Conditions
HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer
Interventions
palbociclib, trastuzumab, pertuzumab, letrozole, Anastrozole, Exemestane, Fulvestrant
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
35
States / cities
San Francisco, California • Washington D.C., District of Columbia • Clearwater, Florida + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Jun 25, 2026, 3:10 PM EDT
Completed Phase 1 Interventional

Endoxifen in Adults With Hormone Receptor Positive Solid Tumors

NCT01273168
View directory record Official record
Conditions
Hormone Receptor-Positive Breast, Gynecologic, Desmoid, Hormone Receptor-Positive Neoplasms
Interventions
Z-Endoxifen
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Jun 25, 2026, 3:10 PM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

NCT07062965
View directory record Official record
Conditions
Breast Cancer
Interventions
PF-07248144, Fulvestrant, Everolimus, Exemestane
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
102
States / cities
Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jun 25, 2026, 3:10 PM EDT
Completed Phase 2 Interventional Results available

Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

NCT01560416
View directory record Official record
Conditions
Breast Cancer
Interventions
Fulvestrant, Ganetespib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
5
States / cities
Boston, Massachusetts • Concord, New Hampshire • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Jun 25, 2026, 3:10 PM EDT
Completed Not applicable Interventional

S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer

NCT01515800
View directory record Official record
Conditions
Breast Cancer
Interventions
Text message reminder
Behavioral
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
724 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
204
States / cities
Anchorage, Alaska • Fort Smith, Arkansas • Little Rock, Arkansas + 144 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Jun 25, 2026, 3:10 PM EDT
Recruiting Phase 1 Interventional

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

NCT07318805
View directory record Official record
Conditions
Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Triple Negative Breast Cancer
Interventions
PF-08032562, Fulvestrant, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
9
States / cities
Duarte, California • Grand Rapids, Michigan • Conroe, Texas + 5 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jun 25, 2026, 3:10 PM EDT
Terminated Phase 2 Interventional Results available

Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer

NCT03289039
View directory record Official record
Conditions
Breast Cancer
Interventions
Neratinib, Fulvestrant
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
6
States / cities
Indianapolis, Indiana • Brewer, Maine • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jun 25, 2026, 3:10 PM EDT
Completed Phase 3 Interventional Results available

S0927:Omega3-Fatty Acid Supp in Treating Muscle&Bone Pain&Stiffness in Pts W/Stg I,II,III Brst Canc Rec'v Hormone Thpy

NCT01385137
View directory record Official record
Conditions
Arthralgia, Breast Cancer, Pain
Interventions
omega-3 fatty acid, placebo
Dietary Supplement · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
292
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 215 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Jun 25, 2026, 3:10 PM EDT
Recruiting Phase 2 Interventional

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

NCT06176261
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Female, Metastatic Triple-Negative Breast Carcinoma, ER Positive Breast Cancer, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, ER-negative Breast Cancer
Interventions
Datopotamab Deruxtecan
Drug
Lead sponsor
Sarah Sammons, MD
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
Miami, Florida • Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Jun 25, 2026, 3:10 PM EDT
Completed Phase 3 Interventional

Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer

NCT00002967
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, doxorubicin hydrochloride, octreotide pamoate, tamoxifen citrate
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
106
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 87 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Jun 25, 2026, 3:10 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial for Large ER-Negative Breast Cancers

NCT01869192
View directory record Official record
Conditions
Malignant Neoplasm of Female Breast
Interventions
Epirubicin, Cyclophosphamide, Docetaxel, Capecitabine, Radiation Therapy
Drug · Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Jun 25, 2026, 3:10 PM EDT